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SUMMARY 
Scrapie is an infectious neurologic disease in sheep caused by prions, corre-
sponding to transmissible spongiform encephalopathies (TSEs) in other species. 
The prion is presumably constituted of PrPSc, the misfolded form of the normal 
endogenous prion protein, PrPC, which is found in practically all cells in the body. 
PrPSc can induce a conformational change in PrPC and misfold it as an imprint of 
itself; this is how prions amplify and spread. The process of conformational 
change is poorly understood and there might exist intermediate forms between 
PrPC and PrPSc. Bioassay using mice has traditionally been the golden standard in 
prion studies but is limited by cost and time. Cell culture studies are now used but 
often rely on using so called rodent-adapted strains and/or cells overexpressing 
the prion protein. 
In this study we made an attempt to infect FLK-BLV cells (ovine cells 
persistently infected with bovine leukemia virus) with brain material from a 
Swedish scrapie case in 1986. We have also developed a sensitive western blot 
assay that detects prion formation but also conformational changes in the prion 
protein. Digestion with proteinase K for different periods of time is used to 
establish conformation. No PrPSc was formed in the inoculated cells but there 
were indications of increased resistance to proteinase K, perhaps reflecting an 
intermediate form of the prion protein in the cells. Further studies on this cell 
system are needed before substantial conclusions can be made. 
SAMMANFATTNING 
Scrapie är en infektiös neurologisk sjukdom hos får orsakad av prioner, 
motsvarande transmissibla spongiforma encefalopatier (TSE) hos andra arter. 
Prioner består av PrPSc vilket är den felveckade formen av det cellegna 
prionproteinet, PrPC, som finns i praktiskt taget alla celler i kroppen. PrPSc kan 
inducera en konformationsändring i PrPC i vilken den senare felveckas att likna 
PrPSc; det är på detta sätt som prioner mångfaldigas och sprider sig. Processen 
bakom konformationsändringen är i stort okänd och det kan finnas intermediära 
former mellan PrPC och PrPSc. Traditionellt har djurmodeller med möss använts 
inom prionforskningen men detta är kostsamt och tidskrävande. Studier i 
cellkulturer används numer men dessa är ofta beroende av musadapterade 
stammar och/eller överuttryck av prionproteinet i cellerna. 
I denna studie har vi försökt infektera FLK-BLV-celler (ovina celler persistent 
infekterade med bovint leukemivirus) med hjärnmaterial från det svenska scrapie-
fallet 1986. Vi har även utvecklat en känslig western blot-analysmetod som 
undersöker förekomst av prioner men även konformationsändring. Detta görs 
genom att digerera prionproteinet med proteinas K under olika lång tid. I studien 
fann vi inget PrPSc men det finns indikationer på en ökad resistens mot proteinas 
K vilket kan tyda på intermediära former av prionproteinet i cellerna. Fortsatta 
studier på detta cellsystem behövs för att kunna dra några betydande slutsatser. 
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INTRODUCTION 
Scrapie 
History 
Scrapie is a disease in sheep and goats that has been known for more than two 
hundreds years; the earliest descriptions of the disease are from the mid 18th 
century. The neuronal vacuolization in the brains of scrapie-sick sheep, typical of 
all TSEs, were discovered as early as in the late 19th century. In the 1920s it was 
suspected that scrapie was a contagious disease and in 1939 the first successful 
experimental transmission of scrapie was reported (reviewed in Aguzzi & 
Polymenidou, 2004). Despite this it was not until quite recently that the agent 
behind the disease, and other TSEs, was found. In 1982 Prusiner presented his 
hypothesis that scrapie was caused by an agent, partially or fully, constituted of 
proteins and at the same time introduced the concept prion (Prusiner, 1982). This 
hypothesis has been refined and is now generally accepted although not yet 
proved (Weissmann, 2004). Of the TSEs, scrapie has been known for the longest 
period of time and is also the most widespread (Bulgin & Melson, 2007) and has 
thus been studied the most (Hunter, 1998). 
Pathogenesis 
The disease mainly affects blackface sheep breeds, for example Suffolk and 
Hampshire. It is also linked to polymorphisms at three codons, amino acids 136, 
154 and 171 (Bulgin & Melson, 2007). The alleles VRQ and ARQ predispose for 
disease whereas ARR is associated with resistance to disease (the letters represent 
the amino acids of the three codons where V stands for valine, R for arginine, Q 
for glutamine and A for alanine) (Jeffrey & Gonzalez, 2007). 
 
Figure 1. Histologic view of brain with prion disease showing the characteristic 
vacuolation (arrows). Picture is public domain and modified by author. 
The disease is characterized by vacuolation, astrocytosis and neuronal loss in the 
brain (see figure 1), although all these changes are not always seen. It is also asso-
ciated with accumulation of abnormal forms of the prion protein, PrPSc (prion 
protein scrapie), in the brain. The neuroanatomical distribution differs by differ-
ent scrapie strains and sources (Jeffrey & Gonzalez, 2007). PrPSc deposits in the 
brain can be seen as amyloid fibers, diffuse deposits or plaques (Riesner, 2003). 
The pathogenesis doesn’t include any inflammatory response (Hunter, 1998). 
Accumulation of PrPSc occurs initially in central nerves that have connection with 
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the enteric nervous system (ENS), for example the vagus nerve. It is assumed that 
neuroinvasion follows infection of the ENS after acquiring the prion orally 
(Jeffrey & Gonzalez, 2007). 
In animals with clinical disease PrPSc can be found in the peripheral nervous 
system, blood as well as in all lymphoid tissue except thymus, in addition to the 
CNS (Terry et al., 2009; Jeffrey & Gonzalez, 2007). The cause of clinical disease 
in scrapie is probably not due to the morphological signs of vacuolation, astrocy-
tosis and neuronal loss. There are at least no relation between area of neuronal 
loss and the nature of mental changes. Because of vague early symptoms it is hard 
to find a correlation between morphological changes and the clinical deficits 
(Jeffrey & Gonzalez, 2007). 
Clinical manifestation 
Scrapie is a long-term progressive, invariably fatal, neurologic illness. Signs 
usually appear 18 months to 5 years after exposure. It generally starts with 
impaired social behavior followed by progressive ataxia, fine head tremors and 
cutaneous hypersensitivity. Animals often show progressive weight loss, which 
can become severe, without loss of appetite. Affected animals can also show 
behavior changes such as assuming a fixed stare or becoming aggressive. Hyper-
sensitivity often shows as rubbing or scratching on the back or throwing its head 
back biting at the limbs but also chewing motions and licking air. Ataxia is first 
shown when running; hind- and forelimbs become uncoordinated resulting in a 
“bunny-hopping gait” and when worsened the hind limbs may sway when the 
animal is standing (Bulgin & Melson, 2007). 
Clinical signs last for 1 to 3 months, sometimes longer. In final stages animals 
generally become recumbent and death follows within 1 to 2 weeks after the 
animal is able to right itself (Bulgin & Melson, 2007). In some cases animals die 
after a very short incubation time and/or duration of illness. There are even 
records of animals dying without obvious prior signs (Jeffrey & Gonzalez, 2007). 
These variations are caused by different genotype and strain of scrapie (Bulgin & 
Melson, 2007). 
Diagnosis 
Sheep do not mount an immune response to PrPSc and histological changes can be 
unapparent and all diagnosis is thus based on detection of PrPSc in tissue. The 
golden standard is immunohistochemical testing of post mortem biopsy material 
from brain or lymphoid tissue. Detection of PrPSc prior clinical signs has been 
done in blood, lymph nodes, third eye lid, tongue, retina, rectal mucosa and spinal 
fluid (Bulgin & Melson, 2007). Diagnosis can also be done on brain homogenate 
using western blot (SVA, 2005). The authority responsible for scrapie testing in 
Sweden, the Swedish National Veterinary Institute (SVA), uses an ELISA test as 
screening and western blot for confirmation. The latter is enough to differentiate 
scrapie from Nor98 but immunohistochemistry is still needed to exclude BSE 
(Renström, 2009). 
Disease distribution, prevention and control 
There has only been one known outbreak of scrapie in Sweden when two ewes 
was diagnosed with the disease in 1986 (Elvander et al., 1988). Scrapie exists in 
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most European countries and both Denmark, Norway and Finland (neighbors of 
Sweden) have had cases reported in the last few years (OIE, 2009). In the United 
States the prevalence is between 0.1% and 0.3% and it was presumed to be 0.5% 
before their eradication program (Bulgin & Melson, 2007). In Sweden surveil-
lance testing is done on clinical suspicion and on animals dying without prior 
clinical signs. Routine testing in slaughterhouses was done before but this 
program is terminated (Renström, 2009). In the United States, where scrapie is 
endemic, there are extensive eradication programs based on susceptible and 
resistant genotypes and all sheep that die unexpected is advised for a complete 
autopsy with testing of the brain for scrapie (Bulgin & Melson, 2007). 
Other prion diseases 
Nor98 
Nor98 is an atypical form of scrapie, affecting sheep, which was first diagnosed in 
Norway in 1998 (thus the name). Since then it has been found in most European 
countries (Benestad et al., 2008) as well as in the United States (Bulgin & 
Melson, 2007). It is associated with PrPSc accumulation, just as in scrapie and 
BSE, but shows different patterns on western blot as well as on histopathology 
and immunohistochemistry. It can be experimentally transmitted to both sheep 
and mice but epidemiology and biological features suggests it being non-
contagious. It is speculated that this disease is spontaneous, much like sporadic 
Creutzfeldt-Jakob disease in humans (Benestad et al., 2008).  
Bovine spongiform encephalopathy 
The bovine spongiform encephalopathy (BSE) created a massive epidemic in 
Europe, predominantly in Great Britain, from when first reported in 1987 and the 
following ten years (Bradley, 2002). The total number of infected animals is 
estimated to one million and in 1992 40,000 cattle died of BSE in Great Britain, 
which was the largest annual number of cases (Prusiner, 1997). Since then the 
disease has been decreasing and is now practically extinct (Bradley, 2002). 
It is assumed that the outbreak was caused by modifying the rendering process of 
meat and bone meal (MBM). The change made it possible for prions to survive, 
which created a magnifying cycle process when fed to cattle (Prusiner, 1997). 
Feeding MBM to mammals, and also fish, was later banned. Because of the long 
incubation time, a mean of five years, the cases still accumulated for some time 
before declining (Bradley, 2002). BSE can infect a wide selection of mammals 
including humans where it cause variant Creutzfeldt–Jakob disease. Spreading of 
the disease to humans was the main concern in the BSE crisis (Prusiner, 1997). 
Creutzfeldt–Jakob disease 
Creutzfeldt–Jakob disease (CJD) is a term for several human prion diseases that 
can be sporadic, genetic or infectious. All of them cause progressive dementia and 
ataxia and have typical spongiform appearance in microscopic examination of the 
brain. Sporadic CJD is the most common but it is still considered idiopathic, i.e. 
the cause is unknown. Suggested causes are somatic mutation, horizontal trans-
mission and spontaneous conversion. Familial CJD is caused by different 
hereditary mutations in the prion protein gene that predisposes for misfolding. 
Variant CJD is caused by ingestion of bovine prions from BSE cases. This disease 
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differs from the two previous mentioned by mainly affecting younger people, 
most cases found are people below 40 years. Iatrogenic CJD is caused by 
infection with prion-contaminated tissue, for example some cases of medication 
with growth hormone (Prusiner, 1997). 
Cellular biology of prions 
Protein-only hypothesis 
Prusiner formulated the protein-only hypothesis about 25 years ago, arguing that 
the scrapie agent is mainly or solely constituted of proteins. He showed that the 
agent is unaffected by methods that modify or destroy nucleic acid but methods 
that affect proteins inactivates its infectivity. This was done after noticing that the 
scrapie agent was unusually resistant to radiation and UV lightning (Prusiner, 
1982). He named the agent prion and later defined that “[a] prion is a proteina-
ceous infectious particle that lacks nucleic acid” (Prusiner, 1998). 
Table 1. Some arguments for the protein-only hypothesis, modified from Prusiner (1998). 
1. PrPSc and scrapie infectivity copurify when biochemical and immunologic 
procedures are used. 
2. The unusual properties of PrPSc mimic those of prions. Many different procedures 
that modify or hydrolyze PrPSc inactivate prions. 
3. Levels of PrPSc are directly proportional to prion titers. 
4. No evidence exists for a virus-like particle or nucleic acid genome. 
5. Accumulation of PrPSc is invariably associated with the pathology of prion 
diseases, including PrP amyloid plaques that are pathognomonic. 
6. PrP gene mutations are genetically linked to inherited prion disease ad cause 
formation of PrPSc. 
7. Knock out of the PrP gene eliminates the substrate necessary for PrPSc formation 
and prevents both prion disease and prion replication. 
 
Final proof of the protein-only hypothesis is still lacking (Caughey & Baron, 
2006) but several features make it evident that the prion is actually the agent for 
scrapie and other TSE’s as seen in table 1 (Prusiner, 1998). The strong, but not 
complete, resistance to degradation with proteinase K (PK) supports the prion 
hypothesis. The idea of different isoforms of the protein was developed after the 
finding of non-resistant forms of the same protein in non-infected (Riesner, 2003). 
Maybe the strongest support for the protein-only hypothesis is that knockout mice 
without the normal prion protein PrPC, so called Prnp0/0 mice, are resistant to 
prion disease (Weissmann, 2004). Many attempts have been done to falsify the 
protein-only hypothesis, mainly focusing on finding foreign nucleic acid, but all 
have been unsuccessful (Safar et al., 2005b). 
Endogenous PrPC 
The normal, endogenous, prion protein PrPC (prion protein cellular) can be found 
in many different cell types in both mammals and other species (Ford et al., 
2002). Its presence in neuronal cells in the brain is of most concern, at least when 
considering prion diseases. The chemical properties of the prion protein are well 
known but its biological function is far from clear (Riesner, 2003). 
 10 
The prion protein is a N-linked glycoprotein bound to the cell membrane by a 
glycosylphosphatidylinositol (GPI) anchor. Depending on species it is approxi-
mately 200 amino acids in length and has a N-terminal region (residues 23-125) 
and a C-terminal region (residues 126-231) as seen in figure 2. The N-terminal is 
an unstructured and flexible tail whereas the C-terminal forms three alpha helices 
and one short beta sheet (Ronga et al., 2006). The N-terminal includes two 
hexarepeats and five octarepeats (Riesner, 2003). The protein is translated in the 
endoplasmatic reticulum where residues 1 to 22 act as a signal peptide and is 
therefore cleaved. After that it gets glycosylated (mono- or di-) in the Golgi 
apparatus before transportation to the cell membrane (Riesner, 2003; Caughey & 
Baron, 2006). Residues 232 to 254 are replaced with the GPI-anchor needed for 
cell membrane attachment (Riesner, 2003). 
 
Figure 2. The tertiary structure of the prion protein (human). Shows the three alpha 
helices, the beta sheet and the octarepeat. Glycosylation or GPI-anchor is not shown. 
From Ronga et al. (2006). 
In the cell membrane PrPC is located in so called lipid rafts which are cholesterol 
rich areas with generally a lot of surface receptors and cytoplasmic signaling 
molecules. Some propose that PrPC binds to some of these molecules and that it 
might have a function in cell signaling (Taylor & Hooper, 2006). It has also been 
shown that PrPC binds to many other different structures such as sulphated 
glycosaminoglycans (GAGs) and extracellular-matrix proteins. It also binds 
copper in the form of Cu2+ within the octarepeats. The reason to this is unknown 
but it doesn’t happen with other divalent cations (Ronga et al., 2006). 
Formation and structure of PrPSc 
PrPC and PrPSc have the same primary structure but differ in their secondary and 
tertiary structure. Where PrPC has about 40% of alpha helices and very little beta 
sheets, PrPSc consists of about 20% alpha helices and 34% beta sheets. The exact 
tertiary structure of PrPSc is unknown as it is insoluble which makes analysis with 
X-ray or nuclear magnetic resonance difficult (Riesner, 2003). After moderate 
digestion with proteinase K a fragment of about 27-30 kDa will remain, which for 
example can be detected using western blot. This fragment is called PrP27-30 and 
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shares many characteristics with PrPSc, for example its infectivity. Depending on 
strain the cleavage is done at amino acids 87 – 91 (Weissmann, 2004). 
Formation of beta sheet rich PrPSc always leads to oligomerization. Larger such 
structures can be seen in electron microscopy as fibrillar rods, being amyloid 
fibers (Riesner, 2003). The alpha2-helix of amino acids 173-195 has strong pref-
erence of conversion to beta sheet, and this could be a key area for conversion of 
PrPC to PrPSc. This area has also been shown to be an oligomerization site (Ronga 
et al., 2006). PrPSc is membrane bound just as PrPC unless accumulated as 
amyloid fibers (Riesner, 2003). Knockout mice lacking the GPI anchor (with the 
PrP not membrane bound) don’t get clinical disease, showing that anchoring is a 
prerequisite for toxicity (Ronga et al., 2006). If the prion protein is located out of 
the lipid raft, by experimentally changing the membrane anchor, it can also not be 
converted to PrPSc (Taylor & Hooper, 2006). 
Propagation of PrPSc 
Studies with cell cultures have shown that conversion of PrPC to PrPSc occurs on 
the cell surface. PrPSc induces a conformational change in PrPC to adopt its 
structure and probably adding to a PrPSc oligomer. PrPSc can be accumulated on 
cell surface, in intracellular vesicles or in extracellular deposits. The most infec-
tious unit of PrPSc has shown to be non-fibrillar oligomers of 14 to 28 PrP-
molecules (Caughey & Baron, 2006). It is possible, or even probable, that another 
substance is needed for propagation. This substance has earlier been designated 
“Protein X” but could perhaps be glycosaminoglycans or host-derived nucleic 
acid (Weissmann, 2004; Caughey & Baron, 2006). The fact that localization to 
lipid rafts is necessary for conversion supports the hypothesis of a co-factor. 
There are two explanation models for PrPSc propagation, the template-directed 
refolding model and the seeded nucleation model, as shown in figure 3. 
Template-directed refolding 
The template-directed refolding model, also called the refolding model, propose 
that PrPC cannot convert spontaneously to PrPSc within detectable levels. PrPSc 
works as a template and causes a conformational change in PrPC. This could be 
facilitated by some other structure. Spontaneous formation can occur as a rare 
event or secondary to a mutation that makes PrPC instable (Weissmann, 2004). 
Seeded nucleation 
The seeded nucleation model argues that PrPC and PrPSc are in equilibrium, 
although highly shifted towards PrPC. “Seeds” of PrPSc oligomers serve as foci for 
stabilization and accumulation of PrPSc that lead to further propagation. Seed 
formation is assumed to be slow whereas subsequent addition of single PrPSc 
molecules occurs rapidly. Larger aggregates have to be fragmented to create more 
numerous seeds for the infection to spread (Weissmann, 2004). 
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Figure 3. Brief schematics of the two main prion propagation models. From Weissmann 
(2004). 
Species barrier 
Transmission between mammalian species is far less effective than within species 
and this is called the species barrier. Generally, in an initial passage from species 
A to B not all animals get infected and the incubation time is longer (than within 
the same species). For subsequent transmissions from B to B, parameters 
resemble intra-species transmission. Even though prions propagate easier if the 
primary structure is identical (same host species) some characteristics are kept 
even if passaged through another species. For example does vCJD infect mice 
whereas classical CJD doesn’t despite both of them having the same primary 
structure (Collinge & Clarke, 2007). 
Prion strains 
A concept somewhat related to the species barrier is prion strains. These strains, 
constituted of different prion agents, were originally characterized by incubation 
time and neuropathology. Nowadays we also see differences in resistant to 
proteinase K-digestion, cleavage sites (forming different fragment sizes), stability 
to denaturation agents and the ratio of un-, mono- and diglycosylation 
(Weissmann, 2004). Strains cannot be defined from the protein’s primary 
structure because characteristics are kept if passaged through another species 
(Collinge & Clarke, 2007) and even if passaged in cell culture and then inoculated 
back to an animal (Vilette, 2008). Strains passaged through another species is said 
to be adapted and for example are rodent-adapted strains widely used (Collinge & 
Clarke, 2007). 
It is not clear how a polypeptide or protein can encode multiple disease pheno-
types. Different isoforms of the PrP are assumed to be the cause and in that case 
these have to be able to imprint their conformation on PrPC. The fact that strains 
have different fragment sizes (when digested with proteinase K) supports this idea 
(Collinge & Clarke, 2007). However, this hypothesis demands a vast number of 
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conformations of the prion protein, although they could to some part be consti-
tuted of poly- and oligomers (Weissmann, 2004). Glycosylation could also be a 
part to this concept as glycosylation ratio is a strain characteristic. The prion 
strains can mutate, mainly if transferred to a new host or if the primary structure is 
different (as in polymorphism) but even among animals with the same primary 
structure. Some strains are more prone to mutate than others (Collinge & Clarke, 
2007). 
Other prion hypothesis 
Some still advocate that TSE’s are probably not caused by prions but instead a 
small virus or virion. Manuelidis (2007), for example, argues that prions do not 
fulfill Koch’s postulate for infection, pointing out that no recombinant or artificial 
prions have ever been created. There are also claims of a 25-30 nm large virus-
like particle associated with infectious homogenates. The virus hypothesis is also 
supported by the fact that PrPSc concentration is not proportional to infectious 
titers (Manuelidis, 2007). 
Assay techniques 
Most assays for prions rely on detecting proteinase K-digested PrPSc since it is 
easily separated from endogenous PrPC. Type of sample and method differs; those 
mainly used are Western blotting, enzyme-linked immunosorbent assay (ELISA) 
and immunohistochemistry. Animal bioassay, inoculation of test animals, is also 
used extensively and has until for a few years ago been the golden standard. 
Today other techniques match the reliability and accuracy of the bioassay. 
However, all other methods assume that PrPSc is identical with the prion, so for 
infectivity analysis bioassay is still needed (Sakudo et al., 2007). 
There is no method that can detect proteins as well as there are for nucleic acid 
(Galbraith, 2002). Quite recently, though, a protein misfolding cyclic amplifica-
tion (PMCA) method was described that can amplify infectious titers of PrPSc. 
This can enhance the sensitivity for many of the assays. There exist both antibod-
ies and aptamers that can discriminate between PrPC and PrPSc although these 
have not yet been sufficiently evaluated and are not used in practice. Aptamers are 
nucleic acid or peptides that specifically binds to a target protein, much like an 
antibody (Sakudo et al., 2007). 
Immunohistochemistry 
Immunohistochemistry is done on formalin fixed or frozen tissue samples. The 
method detects PrPSc in situ, which means both detection for diagnosis and the 
distribution in tissue (Grathwohl et al., 1997). It can be used for many different 
tissues and organs. It is considered to be the golden standard for prion diagnosis in 
the US and is also confirmatory test at some of the World Health Organization’s 
laboratories (Bulgin & Melson, 2007). 
Western blot 
Western blot, or protein immunoblot, is a method to detect proteins in a given 
sample. It consists of a gel electrophoresis, which separate the proteins depending 
on size or structure, after which the proteins are transferred to a membrane. 
Proteins are then visualized using primary antibodies, directed towards the sought 
 14 
protein, and a marked secondary antibody. Marker can be based on chemilumi-
nescent or radioactivity, for example (Abbas et al., 2010). 
As you can also see glycosylation of proteins on Western blot, the prion protein 
will show itself as three bands representing the un-, mono- and diglycosylated 
form. With diglycosylation treatment, for example with PNGase F, you will only 
see the full-length protein (and the C1 fragment). With proteinase K digestion, 
PrPC will disappear but PrPSc will remain. PrPSc will be somewhat cleaved and 
shifted downwards and show as a 27 - 30 kDa fragment, PrP27-30 (or its glycosy-
lated forms) (Weissmann, 2004). 
Different prion strains have different glycosylation pattern depending on the 
strain. Thus, with Western blot you can differentiate between strains, and also 
between BSE, scrapie and the different forms of CJD (Sakudo et al., 2007). 
ELISA 
Enzyme-linked immunosorbent assay (ELISA) is used to identify antigen or 
antibodies. When detecting the agent, an antibody bound to an enzyme is added to 
the sample. After this a substance is added that the linked enzyme can convert to a 
detectable signal. Most new ELISAs use fluorescence for detection (Abbas et al., 
2010). 
For some ten years, ELISAs for prion diagnosis has been available that match the 
sensitivity of Western blot. Since this method is fast this has reduced the analysis 
time, although it still needs time-consuming sample preparations (Grathwohl et 
al., 1997). Today there is at least four ELISAs used in the EU for surveillance on 
scrapie although none of these has been validated in the US (Bulgin & Melson, 
2007). 
Bioassay 
Intracerebral inoculation on sheep and goats as bioassay was done as early as in 
the 30s and later on scientists began to work with rodents (Galbraith, 2002). 
Initially mice were used and about 60 mice were needed for the titer of one 
sample and it took more than 12 month. With the “incubation time bioassay” and 
using Syrian hamsters only four animals are needed. This reduced incubation time 
to 70 days speeding up research almost 100-fold (Prusiner, 1998). 
Today, animal studies are the golden standard for detection of prion infectivity 
(which not necessarily has to be the same as PrPSc). Recently, transgenic mice that 
overexpress PrPC have led to even shorter incubation times (Kocisko & Caughey, 
2006). Mice that express species-specific PrPC without any background (no 
endogenous PrPC) are generally used as these are very sensitive to infection 
(Grathwohl et al., 1997). Incubation time in mice is shorter and less variable with 
higher doses of agent. However this also reduces the possibility to test anti-prion 
substances, which in one major reason for bioassays. For an incubation time of 
about 70 days in the Tg7 mouse it is needed 50 µl of 0.001% infectious brain 
homogenate, but higher dosage can reduce the time to 44 days (Kocisko & 
Caughey, 2006). 
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Prions in cell culture 
Cell cultures can propagate prions with maintained infectivity. This allows for 
easier research on the cell biology of PrPC as well as PrPSc, the pathophysiology 
of prion disease and to determine strain characteristics. Cell cultures can also be 
used in diagnosis (Solassol et al., 2003) and is of value when looking at the 
genetic basis for prion infection (Vilette, 2008). 
Several cell lines are permissive to rodent-adapted strains of prions. Cells of 
neuronal origin are most common but for example fibroblasts, muscle cells and 
microglial cells are also used. The most used cell lines are the N2a (mouse neuro-
blastoma) and the RK13 (rabbit kidney epithelia) cell lines. In 2001 the first 
successful attempt to infect a cell culture with natural TSE agent was done. As of 
now there are three known cell models for natural scrapie agent, two of these are 
from ovine transgenic mice and one are rabbit cells expressing the ovine prion 
protein (see table 2). No cell model for Creutzfeldt–Jakob disease or bovine 
spongiform encephalopathy exists yet. Generally each cell line is only susceptible 
to one or a few scrapie strains and the polymorphism in the sheep prion protein 
plays an important role (Vilette, 2008). 
Table 2. A few of the available cell lines susceptible to prion infection. Modified from 
Vilette (2008). 
Cell line Original cell type Species Comment 
Rodent-adapted strain  
N2a Neuroblastoma Mouse  
GT1 Hypothalamic cells Mouse  
moRK13 Kidney epithelial cells Rabbit RK13 with mouse PrPC 
PC12 Pheochromocytoma Rat  
Natural scrapie agent  
ovRK13 Kidney pithelial cells Rabbit RK13 with ovine PrPC 
MovS Schwann-like from 
dorsal root ganglia 
Transgenic mice Mice with ovine PrPC 
CGNov Neuronal cells Transgenic mice Mice with ovine PrPC 
 
Basically, infection of cell cultures with prions is done by incubating the cells 
with a prion preparation, e.g. brain homogenate. Some studies show that the 
infection is much more efficient if using already infected living cells as inoculum 
(Kanu et al., 2002). On the other hand, when using brain homogenate, prior 
sonication and treatment in 80°C reduce the risk of bacterial and viral contamina-
tion and reduce toxicity to cells (Solassol et al., 2003). Overexpression of PrPC is 
not required but a similarity in the primary sequence of the cell line and the 
inoculum is thought to be essential (Weissmann, 2004). Infecting the cell cultures 
with some retroviruses has proven to increase both the susceptibility and the 
accumulation of prions (Leblanc et al., 2006; Stanton et al., 2008). Table 3 shows 
a short summary of some protocols used when infecting cell cultures with prions. 
To create a permanently infected cell culture the propagation of the prion needs to 
be within certain limits. Splitting cells to often in relation to propagation will 
dilute the prions and they will disappear, splitting them to seldom and you will 
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reach an upper level of toxicity leading to cell death. This has been called the 
“dynamic susceptibility model” (Weissmann, 2004). It has also been shown that 
cell cultures can degrade PrPSc, which further supports the idea that infection is 
more about balance than simply an on/off-state (Vilette, 2008). 
Table 3. Different protocols used for cell infection with prions. In some protocols more 
medium is added after a while and cells are incubated further, thus “initial” and 
“secondary” incubation. “Rest phase” refers to the time from washing the cells to 
splitting. 
Reference Homogenate 
preparation 
Homogenate 
concentration 
Initial 
incubation 
Secondary 
incubation Rest phase 
Bosque & 
Prusiner, 2000 None 0.33% 4 days None None 
Vilette et al., 
2001 
Heating and 
sonication 2.5% 6 h 48 h 60 h 
Kanu et al., 
2002 Sonication 2% 5 h 18 h 
Until 
confluent 
Archer et al., 
2004 None 2.5% 4 days None 24 – 48 h 
Lehmann, 2005 None 2% / 0.2% 5 h 14 – 16 h 24 h 
Vella et al., 
2007 None 1% / 0.1% 5 h 72 h None 
Courageot et 
al., 2008 Sonication 2.5% 48 h None None 
Lawson et al., 
2008 None 1% / 0.1% 5 h 72 h None 
 
Aim of project 
The aim of this project was to infect FLK-BLV cell cultures with prions from a 
scrapie-infected brain from one of the Swedish cases in 1986. As a part of this we 
looked for a new more sensitive assay to detect infection of prions in cell culture. 
This cell line could create new possibilities to investigate prion protein conforma-
tional changes as well as a basis for therapeutic research. 
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MATERIAL AND METHODS 
Cell line 
Fetal Lamb Kidney cells permanently infected with Bovine Leukemia Virus (cell 
line 44/2), denoted FLK-BLV, (Van Der Maaten & Miller, 1975) were acquired 
from Svanova Biotech, Uppsala. All cell cultures were maintained in Dulbecco’s 
Modified Eagle’s Medium (DMEM; Lonza) supplemented with 100 IU/ml 
penicillin, 200 µg/ml streptomycin, 2 mM L-glutamine and 5% Fetal Calf Serum 
(Invitrogen) and this solution is further denoted DMEMcomplete. Cell cultures 
were kept at 37°C in a humidified atmosphere with 5% CO2 in a HERAcell 
incubator (Heraeus). 
Brain material 
Frozen brain material from one of the two Swedish scrapie cases in 1986, journal 
number 311/86, was a gift from SVA (Marianne Elvander). Preparation of brain 
homogenate was done according to Lawson et al. (2008). 0.18225 g of brain 
material was added to 9 volumes, 1.64 ml, of PBS. This was passed through 18, 
23 and 26 gauge needles. When needed, gross cellular debris was removed with a 
clearing spin at 100 g for 1 min. Aliquots of 200 !l homogenate were stored in 1.5 
ml microtubes at -20°C. 
Infection of FLK-BLV cell cultures 
Brain homogenate was sonicated three times 15 seconds with 45-second breaks, 
heated to 80°C for 20 minutes and then centrifuged at 8,000 g for 10 seconds and 
cooled to room temperature. The homogenate was diluted with 4 volumes of 
DMEMcomplete to a brain homogenate concentration of 2%. 2 ml of this solution 
was added to a 25 cm2 flask with FLK-BLV cells at 70% confluence and inocu-
lated for 5 hours at 37°C. After initial incubation, 2 ml DMEMcomplete was 
added and the cell culture was incubated for 67 hours at 37°C. Brain homogenate 
was then removed by rinsing the cell culture twice with PBS before incubating for 
72 hours in DMEMcomplete. 
Day 6 post infection the cell culture was transferred from the 25 cm2 flask to a 75 
cm2 flask. Day 13, 20 and 27 after infection one cell culture flask was split 1 to 3. 
Splits were performed by rinsing cells with PBS before incubating with trypsin at 
37° until cells loosened from the flask, approximately 10 minutes. Trypsinized 
cells were transferred to new flasks and maintained in DMEMcomplete. 
Cell extraction 
Cell cultures, both normal and those incubated with scrapie material, were lysed 
in lysis buffer (0.5% Triton X-100, 0.5% Sodium deoxycholate, 5 mM Tris-HCl 
pH 7.5, 150 mM NaCl, 5 mM EDTA) and incubated for 10 minutes at 0°C. 1 ml 
lysis buffer was used for one 75 cm2 flask and confluent cell cultures were used. 
Lysates were then clarified by centrifugation at 3,000 g for 5 minutes at 5°C and 
supernatants were transferred and stored at -20°C until analysis. 
Cell lysates of the infection trial cultures were made day 20, 27 and 34 post 
infection. Two flasks were lysed each time. Cell lysates from normal FLK-BLV 
cell cultures were made continuously. 
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Proteinase K digestion 
In the assay evaluation prestudy, cell lysates and brain homogenate were either 
left undigested or digested with proteinase K (PK; Sigma) at a concentration of 
either 50 µg/ml or 10 µg/ml for 30 minutes at 37°C. Undigested samples were 
corrected with lysis buffer to make the same total volume. Digestion was 
terminated by addition of 5 mM phenylmethylsulphonyl fluoride (PMSF) and 
incubation for 10 minutes at room temperature. 
To test the efficiency of proteinase K, cell lysates from uninfected FLK-BLV cells 
were subject to digestion with PK at a concentration of 2 µg/ml for 1, 2, 4, 8, 15, 
30 and 60 minutes at 37°C. One undigested sample was used as reference. PK 
digestion was stopped as described above. 
In the infection trial analysis, cell lysates were digested with PK at a concentra-
tion of 2 µg/ml for 2, 10 and 50 minutes as well as having one sample left undi-
gested as reference. PK digestion was stopped as described above. 
Deglycosylation and protein precipitation  
Denaturation of all samples was done by boiling with 10% Denaturation Buffer 
(New England BioLabs) for 10 minutes at 100°C. For deglycosylation, PNGase F 
(500,000 U/ml; New England BioLabs) was used in combination with 10% G7 
buffer (New England BioLabs) and 10% NP40 (New England BioLabs) for 120 
minutes at 37°C. Samples were then precipitated using trichloroacetic acid (TCA) 
for 30 minutes at 4°C and centrifugation at 18,000 g for 10 minutes at 4°C. Pellets 
were washed by suspension in a solution of 50% methanol and 50% acetic acid 
and centrifugation at 18,000 g for 5 minutes at 4°C after which the supernatant 
was removed and pellets were subjected to short evaporation by holding them 
close to a lamp.  
Western blot analysis 
SDS-PAGE and transfer to PVDF-membranes 
Protein pellets were suspended in 30 µl 1x NuPAGE LDS Sample Buffer 
(Invitrogen) with addition of 3 µl 0,1 M dithiothreitol (DTT) and incubated at 
100°C for 10 minutes before loading onto gels. Two markers were used on each 
gel, one with 0,5 µl MagicMark XP (Invitrogen) and 29,5 µl 1x LDS Sample 
Buffer and one with 10 µl SeeBlue Plus2 (Invitrogen), 0,5 µl MagicMark and 19,5 
µl 1x LDS Sample Buffer. These were loaded onto gels without any prior 
treatment. 
SDS-PAGE gel electrophoresis was run with 12% NuPAGE Novex Bis-Tris Gels 
(Invitrogen) with 1x NuPAGE MOPS SDS Running Buffer (Invitrogen) with 200 
µl NuPAGE Antioxidant (Invitrogen) added to the load buffer (70 ml MOPS). 
Electrophoresis was run until the Coomassie G250 stain in the sample buffer 
reached the lower edge. Transfer was done using Hybond–P polyvinylidene 
difluoride (PVDF) membrane filters (GE Healthcare). Filters were first activated 
in methanol and as transfer buffer a solution of 20% methanol, 25 mM Tris and 
192 mM glycine was used. 
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Immunoblotting and visualization 
Non-specific binding sites on the membrane filters were blocked using 5% milk 
powder (Semper) in PBS-Tween (PBST) incubated at room temperature for 60 
minutes and then washed by incubation for 15 minutes in PBST. The monoclonal 
antibody 6H4 of mouse origin (0.56 µg/µl; Prionics AG) was used at a 1:30,000 
dilution in PBST with 1% milk powder. This antibody binds to sheep prion 
protein amino acid residues 147–156 and thus recognizes full-length prion protein 
as well as both C1 and C2 fragments (Korth et al., 1997). The antibody was 
incubated with membrane filters for 60 minutes at room temperature followed by 
four 5-minute washes with PBST. Anti-mouse ECL antibody, HRP linked, (GE 
Healthcare) was then added at a 1:15,000 dilution in PBST with 1% milk powder 
to the membrane filters for 60 minutes at room temperature. Finally, the filters 
were again washed with PBST four times, 5 minutes each. 
For visualization, Immobilon Western chemiluminescent HRP substrate 
(Millipore) was used following immediate detection by exposure to X-ray films 
(Hyperfilm; GE Healthcare). Exposures were done for different periods of time 
and subsequently developed. 
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RESULTS 
Assay evaluation prestudy 
Initially a prestudy was carried out to evaluate the proposed assay. The expression 
of cellular prion protein, PrPC, in the FLK-BLV cell culture was investigated. This 
cell culture express detectable amount of PrPC (Tommy Linné, unpublished data) 
and it has been shown in other cell lines that retroviruses can enhance the suscep-
tibility to, and accumulation of, PrPSc (Leblanc et al., 2006). The brain 
homogenate from the scrapie-infected sheep was analyzed for the presence of 
both PrPC and PrPSc. Also the first passage of a previous infection trial (not 
mentioned further in the report) was analyzed for the presence of PrPC and PrPSc. 
These samples were analyzed with two different concentrations of proteinase K 
and two different cell lysis sample volumes. In this study the western blot detects 
the normal and abnormal forms of the prion protein as well as the size of the 
protein, as indicated by the markers. 
 
 1 2 3 4 5 6 7 8 9 10 
Figure 4. Western blot assay prestudy using the 6H4 antiprion antibody. Lanes 1 to 4 
show the first infection trial: undigested (lane 1), treated with 10 µg/ml PK (lane 2), with 
50 µg/ml PK (lane 3) and the double sample volume treated with 50 µg/ml PK (lane 4). 
Lanes 6 and 8 show FLK-BLV cell lysates with and without 50 µg/ml PK treatment, 
respectively. Lanes 7 and 9 show scrapie brain homogenate with and without 50 µg/ml 
PK treatment, respectively. White arrowhead marks full-length prion protein, grey 
arrowhead marks the C1 fragment and black arrowhead marks the C2 fragment. All 
samples were deglycosylated and proteinase K treatments were done for 30 minutes. 
Lane 5 and 10 are markers showing the protein size. 
The western blot from the prestudy is shown in figure 4. The FLK-BLV cell line 
expresses well above detectable levels of PrPC, as both the full-length prion 
protein and the C1 fragment can be seen (lane 8). This is fully digested after 
treatment with 50 µg/ml proteinase K for 30 minutes. The scrapie brain 
homogenate show both presence of full-length and the C1 fragment when 
undigested. After treatment with 50 µg/ml proteinase K for 30 minutes the C2 
fragment is revealed in the scrapie brain, showing that there are prions in this 
sample. The cells from this infection trial express PrPC but when treated with 
proteinase K there is no C2 fragment indicative of prion infection (lanes 1 – 4). 
This is also valid for the lower concentration of proteinase K (10 µg/ml for 30 
minutes), where the prion protein is still fully digested. 
30 kDa 
20 kDa 
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Proteinase K kinetics study 
To increase the sensitivity of the assay there was a need to find a more appropriate 
proteinase K activity instead of the 50 µg/ml (and 10 µg/ml) for 30 minutes used 
in the prestudy. This is the amount used in practical prion disease diagnosis and 
might not be suitable when using cell culture. A kinetics study was made with the 
aim to find the levels where the full-length and the whole protein (the C1 
fragment) were degraded, respectively. The level of activity was based on 
literature and practical experience.  
 
Time (min):  0 1 2 4 8 15 30 60  
Figure 5. Western blot showing proteinase K kinetics study on FLK-BLV cells. Samples 
was digested with 2 µg/ml proteinase K for the stated times. White arrowhead marks full-
length prion protein, grey arrowhead marks the C1 fragment. All samples were 
deglycosylated. The antiprion 6H4 antibody was used. The first and last lanes are 
markers showing the protein size. 
Figure 5 shows that a treatment with 2 µg/ml proteinase K for 30 minutes is 
sufficient to digest all endogenous PrPC in BLV/FLV cell lysates. Also, the full-
length prion protein is digested after only 2 minutes of treatment. The initial 
increase of the C1 fragment after 2 to 4 minutes indicate that the full-length 
protein is degraded to the C1 fragment. 
Infection trial analysis 
The first infection trial proved ineffectual (data not shown) and is excluded. A 
second infection attempt was done with a different protocol. Cells at three 
passages after infection were compared to a negative control of normal FLK-BLV 
cells. This experiment used a kinetics-based assay for increased sensitivity on 
proteinase K resistance, using four time-points. The concentration of proteinase K 
was set to 2 µg/ml according to the findings in the previous experiment. 
The prion protein in the normal FLK-BLV cells shows the same pattern as the 
previous experiment, as seen in figure 6; the full-length prion protein is digested 
after 2 minutes and the C1 fragment after 50 minutes. In the supposedly infected 
cells a band representing the full-length prion protein is still visible after 2 
minutes in all three passages. In passage 2 of these cells there is also a C1 
30 kDa 
20 kDa 
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fragment still undigested after 50 minutes. These findings could represent an 
increase in proteinase K resistance in the inoculated cells, or reflect a bias as 
either an increased sample size or increased protein content in these samples.  
No band corresponding to the C2 fragment, that would represent the existence of 
prions in the cells, can be seen in the inoculated cells or the negative controls. 
 
Time: 0 2 10 50 0 2 10 50 0 2 10 50 0 2 10 50 
 Normal Passage 1 Passage 2 Passage 3 
Figure 6. Western blot of FLK-BLV cells inoculated with prions (passages 1 to 3), as well 
as a negative control (Normal). Every set of samples are treated with 2 µg/ml proteinase 
K for the stated times. White arrowhead marks full-length prion protein, grey arrowhead 
marks the C1 fragment. All samples were deglycosylated. The antiprion 6H4 antibody 
was used. Unmarked lanes are markers showing the protein size. 
30 kDa 
20 kDa 
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DISCUSSION 
Sensitive prion protein assay 
The traditional way to detect prions in brains of diseased animals using Western 
blot is to digest the sample with a strong treatment of proteinase K prior to 
analysis. If the sample contains the fully misfolded form of the prion protein, 
PrPSc, this will show itself as the truncated partially PK-resistant fragment C2. 
The C2 fragment is easily differentiated from the full-length prion protein and the 
C1 fragment, as well as being the only prion protein band still remaining after 
strong digestion with proteinase K. Instead of the traditional method, this study 
use increased resistance to proteinase K of the normal full-length and the C1 
fragment as an assay for conformational change. Increase in resistance can 
indicate the existence of prion proteins in one or more intermediate conformations 
not equal to either PrPSc or PrPC, but still potentially infectious. 
The first experiment shows three important things. The FLK-BLV cells do 
express PrPC and is a suitable candidate for infection trials. Also, the brain 
homogenate from the scrapie-infected brain do contain PrPSc and can be used as 
an inoculum. Last, no remnant PrPSc from the brain homogenate is seen in the 
inoculated cells, something that could otherwise bias further studies. These 
findings together validate the assay used in the later experiment. The second 
experiment establishes a level of proteinase K activity much more sensitive than 
the traditional method. We determine the breakpoint for when the normal full-
length and the C1 fragment, respectively, is fully digested. These two events 
occur at a proteinase K activity level much lower than the one used in traditional 
scrapie diagnostics and also in some cell culture studies (Vella et al., 2007; 
Lawson et al., 2008). The proteinase K activity for scrapie diagnosis (C2 fragment 
detection) is 50 µg/ml for 30 minutes and we have shown that the full-length 
cellular prion protein is degraded (in the FLK-BLV cells) after 2 minutes at 2 
µg/ml proteinase K; this combined lower time and concentration correspond to an 
almost 400-fold reduction in activity. An assay using a proteinase K activity at 
this level should be able to detect very slight changes in proteinase K resistance of 
the prion protein. 
Intermediate conformations 
There are indications that the inoculated cells in this study display increased 
proteinase K resistance of the prion protein. Digestion times in these cells are 
slightly longer than the normal cells; this finding is obtained with the sensitive 
assay previously mentioned.  
This finding could also be due to bias, that the samples were either larger in 
volume or that they had an increased protein content relative to the normal cells. 
If it actually does reflect an increase in resistance, it is most probably due to con-
formational changes corresponding to intermediate forms of the prion protein. 
These intermediate forms have previously been given the name sPrPSc (sensitive 
PrPSc) and they might constitute a major part of the infectious prion (Safar et al., 
2005a). Whether these intermediates, if existing, will increase in amount in the 
cell culture after several passages cannot be answered with this study. Two 
scenarios seem plausible: 1) there is an intermediate form of PrP in the cells that 
will slowly fold the PrPC into a copy of itself and thus increase the resistance yet 
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more although not creating fully resistant PrPSc, or 2) there is a low undetectable 
amount of PrPSc in the cells creating the intermediate form seen now, but given 
time the PrPSc will eventually propagate above detection limit. Only the second 
alternative would today be considered as a true infection. But if alternative one is 
true and these cells are in fact infectious it would surely shed new light on what 
constitutes the “prion”. 
Therapeutic research 
Given that it exists an intermediate form of PrPSc in the FLK-BLV cells of this 
study, this cell line could be a good candidate for therapeutic research. New 
knowledge suggests that it might not be the amyloid fibrils or PrPSc, but instead 
the intermediate forms, that are the most neurotoxic and are causing the neuronal 
loss characteristic of prion diseases (Ronga et al., 2006). When searching for 
therapeutics in such case, one should focus on finding agents that decrease the 
proteinase K resistance of the prion protein instead of just lowering the titer of 
formed PrPSc. 
Genotype effect 
The genotype of the cells and the scrapie-infected brain has not been considered 
in this study. As mentioned, polymorphism at three codons in the sheep prion 
protein is a critical factor for scrapie susceptibility (Jeffrey & Gonzalez, 2007). 
This is also valid for cell cultures; in ovRK13 cells there is a 104-fold difference 
in susceptibility between the VRQ and the ARR alleles (Sabuncu et al., 2003). 
Assuming there is a difference in genotype in cells and inoculum in this study 
there might be other results from a similar infection trial with the FLK-BLV cells 
if they have the same allele. On the other hand, the formation of intermediate 
prion protein conformations might be a result of having a mismatch in genotype. 
Anyhow, genotyping and possibly repeating this experiment with cell cultures of 
different genotypes can give valuable information on the relation between suscep-
tibility, polymorphism and conformational change of the prion protein. 
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